Brokerages Anticipate Insulet Corporation (PODD) to Announce -$0.11 EPS
Wall Street analysts forecast that Insulet Corporation (NASDAQ:PODD) will report ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Nine analysts have made estimates for Insulet Corporation’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.16). Insulet Corporation reported earnings per share of ($0.05) in the same quarter last year, which would suggest a negative year over year growth rate of 120%. The firm is expected to report its next quarterly earnings results after the market closes on Thursday, November 2nd.
According to Zacks, analysts expect that Insulet Corporation will report full-year earnings of ($0.51) per share for the current year, with EPS estimates ranging from ($0.66) to ($0.36). For the next financial year, analysts expect that the business will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.68) to $0.24. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Insulet Corporation.
Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. The firm had revenue of $110.00 million for the quarter, compared to analyst estimates of $106.23 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. The company’s quarterly revenue was up 26.0% compared to the same quarter last year.
A number of equities research analysts have recently commented on PODD shares. Jefferies Group LLC reiterated a “buy” rating and set a $58.00 target price (up from $48.00) on shares of Insulet Corporation in a research note on Wednesday, August 9th. Canaccord Genuity reiterated a “hold” rating and set a $50.00 target price on shares of Insulet Corporation in a research note on Wednesday, September 27th. BidaskClub upgraded Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Cowen and Company reiterated a “buy” rating and set a $52.00 target price on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, Zacks Investment Research cut Insulet Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Insulet Corporation presently has a consensus rating of “Buy” and a consensus price target of $51.50.
Insulet Corporation (PODD) traded up 1.65% during mid-day trading on Monday, reaching $59.80. 203,398 shares of the company’s stock traded hands. Insulet Corporation has a 12 month low of $30.69 and a 12 month high of $59.99. The company has a 50 day moving average price of $57.54 and a 200-day moving average price of $48.88. The stock’s market cap is $3.47 billion.
In other news, EVP Charles Alpuche acquired 2,500 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were acquired at an average cost of $58.08 per share, for a total transaction of $145,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.
A number of institutional investors have recently made changes to their positions in PODD. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Insulet Corporation by 11.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after acquiring an additional 235 shares during the period. Strs Ohio increased its position in shares of Insulet Corporation by 73.9% during the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,700 shares during the period. SG Americas Securities LLC bought a new stake in shares of Insulet Corporation during the second quarter valued at about $180,000. Teacher Retirement System of Texas bought a new stake in shares of Insulet Corporation during the first quarter valued at about $201,000. Finally, Diversified Trust Co bought a new stake in shares of Insulet Corporation during the second quarter valued at about $205,000.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related stocks with our FREE daily email newsletter.